Medical device firm Retractable's Q3 sales dip

Retractable Technologies

14/11/2025 20:22

Overview

Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year

Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year

Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains

Outlook

Tariffs expected to continue impacting costs in future periods

Uncertainty remains regarding timing of future international orders

Result Drivers

TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025

PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales

INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
$10.10 mln
Q3 Operating Income
-$3.70 mln


Press Release: ID:nBw2MxtN9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)